Note: Ingredients listed on restricted chemical lists
EC/CAS
57-50-1
Name of the chemical
Sucrose, pure C12H22O11
Concentration
N/A
General Information
Revision date
2015-09-09
Product name
ORENCIA (abatacept) Subcutaneous Injection, 125 mg/ml
Product Synonyms
Abatacept Injection, Subcutaneous; CTLA-4 Ig Injection, Subcutaneous; CTLA-4
1.2.1 Relevant identified uses
This material is a finished drug product for patient use. It is used to treat autoimmune disorders. It is a protein
Emergency telephone
Australia (Sydney) +(61)-290372994
Icons in SDS
Company Information
company name
Bristol-Myers Squibb Australia Pty Ltd
GHS Information
Signal word
Danger
Section 2
SECTION 2: Hazards identification
UN Globally Harmonized System (GHS)
2.1 Classification of the substance or mixture
Carcinogenicity - Category 2 Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Signal word
Danger
Hazard statements
Suspected of causing cancer. Causes damage to organs (immune system, teeth) through prolonged or repeated exposure.
Precautionary statements
Do not breathe gas/fumes/vapour/spray/mist Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Use personal protective equipment as required. Wash thoroughly after handling. Do not eat, drink or smoke when using this product.
Further information
0.03% of the mixture consists of ingredient(s) of unknown acute toxicity. 29.5% of the mixture consists of ingredients(s) of unknown hazards to the aquatic environment.